Background
Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability. With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI therapeutics market is anticipated to grow at a Compound annual growth rate (CAGR) of 17.84% to reach US$9.61 billion by 2028.
There is a pressing need to create novel therapeutics to treat SCI due to the exorbitant cost of spinal surgery procedures and related healthcare costs. In parallel, the global exosome market is estimated to grow at a CAGR of more than 34% between 2022 and 2030, reaching a market value of around USD 2,273 million by 2030.
The Case for NurExone Biologic Inc
NurExone Biologic is an exciting company that sits at the forefront of these two fast growing arenas. With their unique ExoTherapies, NurExone is making significant advancements towards becoming a market leader in exosome-based treatment for acute spinal cord injuries. As the company grows, it has announced numerous strategic initiatives, such as plans to expand its intellectual property portfolio and partnerships for advanced research. Moreover, positive preliminary findings prove the company’s potential and distinguish itself as an emerging exosome leader with an intriguing biotechnology portfolio and offering.
New Results Cement NurExone’s Technological Advantage
The company recently announced results from a scientific survey of their exosome-based technology. The results show the effectiveness of the Company’s proprietary small interfering RNA (siRNA) in inhibiting the expression of the phosphatase and tensin homolog (PTEN). Inhibition of PTEN promotes axon regeneration and neural repair, key elements for healing after a traumatic spinal cord injury. These results further establish the potential of the technologies being developed by the company.
An Emerging BioTech Leader
The Future Markets Research Tank released commentary on NurExone Biologic (TSXV: NRX) (FSE: J90) recently, naming them An Emerging Leader In The Exosomal Treatment Of Spinal Cord Injury. The report concludes the following: “As the company continues innovating and achieving meaningful milestones, they are well positioned to become a leading biotech company and central player in both the exosome and the spinal cord treatment arenas.”
